Dr. Stephan Miller and colleagues at the University of Tübingen in Germany have discovered that silent myocardial infarction raises the likelihood of a future major cardiac event for 14% of patients with symptomatic peripheral vascular disease evaluated with MRA.
Dr. Stephan Miller and colleagues at the University of Tübingen in Germany have discovered that silent myocardial infarction raises the likelihood of a future major cardiac event for 14% of patients with symptomatic peripheral vascular disease evaluated with MRA.
They made the finding after developing a new MR protocol that combined delayedenhancement myocardial MRA with a conventional contrast-enhanced peripheral vascular runoff study. The delayed myocardial perfusion images were acquired 10 minutes after MRA using the same 0.18-mmol administration of gadolinium-based contrast media.
Evidence of a previous myocardial infarction appeared for 58 of 182 (32%) patients with confirmed peripheral vascular disease. Twenty-six patients, in consultations after the procedure, admitted that they were not aware of their previous infarction. The clinical relevance of the findings proved themselves out when subjects were interviewed two years later. Major adverse cardiac events, such as unstable angina, revascularization, or cardiac-related death, arose among eight of 26 (31%) patients with an occult progressing infarction. The MACE rate for patients with unknown infarction was 34% and 6% for patients whose delayed-enhancement MRA studies ruled out MI.
Miller concluded that the add-on cardiac sequence is a meaningful supplement to peripheral vascular MRI that provides important information to help physicians stratify patient risk and choose optimal therapy.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.